Abstract
Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Current Pharmaceutical Design
Title:How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease
Volume: 23 Issue: 31
Author(s): Salvatore Santo Signorelli*
Affiliation:
- Department of Clinical and Experimental Medicine, University of Catania; General Medicine Division, University Hospital “G.Rodolico. Catania,Italy
Keywords: Arterial hypertension, peripheral arterial disease, cardiovascular risks, anti-hypertensive drugs, arterial pressure, anti-hypertensive therapy.
Abstract: Background: Arterial hypertension (AH) and peripheral arterial disease (PAD) frequently coincide. While significant attention is paid to AH, PAD is often underestimated. It is known that both AH and PAD present high cardiovascular risks for ischemic events. To date, the use of the most common anti-hypertensive drugs in PAD patients is still under debate.
Methods: Data from studies of large populations and minor cohorts of patients show AH and PAD together or PAD alone. Results: cardiovascular and renal outcomes for PAD patients show lowered arterial pressure. We cannot rank the class of anti-hypertensive drugs recommended for PAD patients with AH. However, optimum targeted anti-hypertensive therapy is strongly recommended by cardiology guidelines.
Conclusion: comprehensive cardiovascular protection is the most important goal in using anti-AH drugs in PAD together with other drugs such as anti-platelets and statins.
Export Options
About this article
Cite this article as:
Signorelli Santo Salvatore*, How to Treat Patients with Essential Hypertension and Peripheral Arterial Disease, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170608083605
DOI https://dx.doi.org/10.2174/1381612823666170608083605 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide
Recent Patents on Drug Delivery & Formulation Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Selectivity Filters to Edit Out Deleterious Side Effects in Kinase Inhibitors
Current Topics in Medicinal Chemistry Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews An Introduction to Obesity and Dementia
Current Alzheimer Research Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Preface: Vitamin D and QT Interval in Epilepsy: More than an Association?
Current Clinical Pharmacology Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study
Current HIV Research Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews A Gastroretentive Drug Delivery System of Lisinopril Imbibed on Isabgol- Husk
Current Drug Delivery Clozapine Safety, 40 Years Later
Current Drug Safety Complex Obesity
Current Pediatric Reviews Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry